In vitro efficacy of intralesional Collagenase Clostridium Histolyticum for the treatment of calcified Peyronie's disease plaques.

Autor: Dullea A; Desai Sethi Urology Institute, University of Miami, 1150 NW 14th St, Miami, FL, 33136, USA., Khodamoradi K; Desai Sethi Urology Institute, University of Miami, 1150 NW 14th St, Miami, FL, 33136, USA., Campbell K; Desai Sethi Urology Institute, University of Miami, 1150 NW 14th St, Miami, FL, 33136, USA., Ghomeshi A; Herbert Wertheim College of Medicine, Florida International University, 11200 SW 8th St, Miami, FL, 33199, USA., Ramasamy R; Desai Sethi Urology Institute, University of Miami, 1150 NW 14th St, Miami, FL, 33136, USA., Ziegelmann M; Department of Urology, Mayo Clinic, Rochester, MN, 55902, USA., Masterson T; Desai Sethi Urology Institute, University of Miami, 1150 NW 14th St, Miami, FL, 33136, USA. tmasterson@miami.edu.
Jazyk: angličtina
Zdroj: International journal of impotence research [Int J Impot Res] 2024 Sep; Vol. 36 (6), pp. 572-575. Date of Electronic Publication: 2023 Jul 31.
DOI: 10.1038/s41443-023-00742-0
Abstrakt: Peyronie's disease (PD) is defined by penile plaque formation and curvature causing sexual dysfunction. The only FDA-approved intralesional treatment is Collagenase Clostridium histolyticum (CCh). CCh contains two collagenases, AUX1 and AUXII, that break down the type I and type III collagen contained in plaques, leading to plaque dissolution and reduction in penile curvature. Peyronie's plaques, however, also contain fibrin and calcium, which CCh cannot digest. It is unclear if plaque calcification prevents CCh from breaking down plaques. We collected ten tissue samples: five calcified penile plaques and five control samples of corpus cavernosum. They were incubated in CCh or PBS. Soluble collagen measurements and collagen staining assays were completed to measure tissue breakdown. Calcified plaques incubated in CCh showed significantly higher levels of soluble collagen (301.07 ug ± 21.28 vs. PBS: 32.82 ug ± 3.68, p = 0.02), and significantly lower levels of collagen (type I and III) compared to tissues incubated in PBS (0.12 ± 0.08, vs. 0.44 ± 0.17, p = 0.002). When comparing different tissues (calcified vs. control) incubated in CCh and PBS solutions, there were no significant differences in collagen staining or breakdown. Although higher collagen staining was seen in the calcified group, soluble collagen showed no significant differences between control and calcified tissues in the CCh group (control: 0.08 ± 0.02 vs. calcified: 0.17 ± 0.09, p = 0.08) or the PBS group (control: 0.50 ± 0.23 vs. calcified: 0.39 ± 0.39, p = 0.23). CCh exposure led to significantly more tissue breakdown in both tissue groups when compared to PBS however, there was no significant difference in plaque digestion found between calcified and control tissue exposed to CCh or PBS. This suggests that plaque calcification does not affect the action of CCh. Further research into CCh for calcified plaques is necessary to inform clinicians as to the optimal management of this population.
(© 2023. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.)
Databáze: MEDLINE
Externí odkaz: